An increase in n-3 dietary/pharmacological intake, a reduction in systemic oxidative mechanisms affecting the n-3 structure, and possibly the use of MCP1 antagonists or agents interfering with its pathway could represent a new strategy for mitigating the detrimental effects of FGF23 in CKD patients. Here, CCL2 is linked to chronic kidney disease.